Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Bitopertin | erythropoietic porphyrias (EPP), X-linked protoporphyria | Phase 3 | Dec 31, 2026 | Mgmt interest |
| DISC-0974 | Myelofibrosis, Anemia | Phase 2 | Dec 31, 2026 | Mgmt interest |
| DISC-0974 (Hepcidin Suppression) | Inflammatory Bowel Disease With Anemia | Phase 2 | Dec 31, 2027 | — |
Upcoming milestones
Company profile
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Polycythemia vera
Data readouterythropoietic porphyrias (EPP), X-linked protoporphyria
Data readout